Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Managing adrenocortical carcinoma with immunotherapies

Matthew Campbell • 10 Sep 2022
ESMO 2022
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Mitotane Pembrolizumab

Matthew Campbell, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential role of immunotherapy in treating adrenocortical carcinoma. Combining immunotherapy with targeted therapies has demonstrated promising efficacy in kidney and thyroid cancer, and clinical trials investigating mitotane and pembrolizumab in adrenocortical carcinoma are currently underway. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Matthew Campbell

2:34
Cabozantinib demonstrates disease control in advanced adrenocortical carcinoma
Matthew Campbell • 10 Sep 2022
0:55
Upcoming updates in GU cancers at ESMO 2022
Matthew Campbell • 10 Sep 2022
0:39
Current first-line therapies for patients with advanced adrenocortical carcinoma
Matthew Campbell • 10 Sep 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals